Role of platelets in restenosis after percutaneous coronary revascularization.
暂无分享,去创建一个
H Le Breton | E J Topol | E. Topol | H. le Breton | H. Breton | E. Plow | E. Plow | E F Plow
[1] E. Topol,et al. Clinical Trials to Prevent Restenosis after Percutaneous Coronary Revascularization , 1997, Annals of the New York Academy of Sciences.
[2] A. Takeshita,et al. Chronic treatment with interleukin-1 beta induces coronary intimal lesions and vasospastic responses in pigs in vivo. The role of platelet-derived growth factor. , 1996, The Journal of clinical investigation.
[3] M. Savage,et al. Effect of thromboxane A2 blockade on clinical outcome and restenosis after successful coronary angioplasty. Multi-Hospital Eastern Atlantic Restenosis Trial (M-HEART II) , 1995, Circulation.
[4] S. Schwartz,et al. Osteopontin and beta 3 integrin are coordinately expressed in regenerating endothelium in vivo and stimulate Arg-Gly-Asp-dependent endothelial migration in vitro. , 1995, Circulation research.
[5] M. Fishbein,et al. VCL, an antagonist of the platelet GP1b receptor, markedly inhibits platelet adhesion and intimal thickening after balloon injury in the rat. , 1995, Circulation.
[6] S. Shattil. Function and Regulation of the β3 Integrins in Hemostasis and Vascular Biology , 1995, Thrombosis and Haemostasis.
[7] E. Topol,et al. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. , 1995, The New England journal of medicine.
[8] R. Califf,et al. Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Platelet Integrin Glycoprotein IIb/IIIa Blocker Integrelin in Elective Coronary Intervention , 1995 .
[9] R. Jordan,et al. Shear-induced platelet aggregation is inhibited by in vivo infusion of an anti-glycoprotein IIb/IIIa antibody fragment, c7E3 Fab, in patients undergoing coronary angioplasty. , 1995, Circulation.
[10] J. Moake,et al. Comparative real-time effects on platelet adhesion and aggregation under flowing conditions of in vivo aspirin, heparin, and monoclonal antibody fragment against glycoprotein IIb-IIIa. , 1995, Circulation.
[11] A. Buchwald,et al. 914-72 Platelet––Stimulated Proliferation of Coronary Smooth Muscle Cells , 1995 .
[12] S. Fujii,et al. 713-1 inhibition of Neointimal Hyperplasia After Balloon Injury by Local Delivery of a Cyclic Arginine-Glycine-Aspartic Acid Peptide Targeting Vitronectin Receptor , 1995 .
[13] J. Zablocki,et al. SC-54684A: an orally active inhibitor of platelet aggregation. , 1995, Circulation.
[14] D. Mehrotra,et al. Extended inhibition of platelet aggregation with the orally active platelet inhibitor SC-54684A. , 1995, Circulation.
[15] S. L. Brown,et al. Stimulation of migration of human aortic smooth muscle cells by vitronectin: implications for atherosclerosis. , 1994, Cardiovascular research.
[16] K. Sakariassen,et al. A perfusion chamber developed to investigate thrombus formation and shear profiles in flowing native human blood at the apex of well-defined stenoses. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.
[17] Joseph F. Murphy,et al. The vitronectin receptor (alpha v beta 3) is implicated, in cooperation with P-selectin and platelet-activating factor, in the adhesion of monocytes to activated endothelial cells. , 1994, The Biochemical journal.
[18] H. Deckmyn,et al. Inhibition of integrin function by a cyclic RGD-containing peptide prevents neointima formation. , 1994, Circulation.
[19] A. Herskowitz,et al. Inhibition of platelet adhesion during cardiopulmonary bypass reduces postoperative bleeding. , 1994, Circulation.
[20] A. Goodall,et al. Aspirin does not affect the flow cytometric detection of fibrinogen binding to, or release of alpha-granules or lysosomes from, human platelets. , 1994, Clinical science.
[21] J. M. Siegel,et al. A scaling law for wall shear rate through an arterial stenosis. , 1994, Journal of biomechanical engineering.
[22] S. Mousa,et al. Intravenous antiplatelet efficacy and safety of the platelet GPIIb/IIIa antagonist, DMP 728 in anesthetized dogs. , 1994, Thrombosis research.
[23] R. Califf,et al. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty. , 1994, Circulation.
[24] T. Yue,et al. Osteopontin-stimulated vascular smooth muscle cell migration is mediated by beta 3 integrin. , 1994, Experimental cell research.
[25] Gail Murphy,et al. Pharmacokinetics and pharmacodynamics of MK‐383, a selective non‐peptide platelet glycoprotein‐IIb/IIIa receptor antagonist, in healthy men , 1994, Clinical pharmacology and therapeutics.
[26] R. Connolly,et al. Selective alpha IIb beta 3 receptor blockage with peptide TP9201 prevents platelet uptake on Dacron vascular grafts without significant effect on bleeding time. , 1994, The Journal of laboratory and clinical medicine.
[27] R. Gould,et al. Non-peptide fibrinogen receptor antagonists. 2. Optimization of a tyrosine template as a mimic for Arg-Gly-Asp. , 1994, Journal of Medicinal Chemistry.
[28] G. Rhodes,et al. The in vivo pharmacological profile of the novel glycoprotein IIb/IIIa antagonist, SK&F 106760. , 1994, The Journal of pharmacology and experimental therapeutics.
[29] M. Todd,et al. Preparation, characterization, and evaluation of a monoclonal antibody against the rabbit platelet glycoprotein IIb/IIIa in an experimental angioplasty model. , 1994, Circulation research.
[30] R. Calvo,et al. The in vitro pharmacological profile of SK&F 106760, a novel GPIIB/IIIA antagonist. , 1994, Thrombosis research.
[31] P. Nurden,et al. Two-way trafficking of membrane glycoproteins on thrombin-activated human platelets. , 1994, Seminars in hematology.
[32] J. Calvete. Clues for Understanding the Structure and Function of a Prototypic Human Integrin: The Platelet Glycoprotein IIb/IIIa Complex , 1994, Thrombosis and Haemostasis.
[33] Z. Ruggeri. New insights into the mechanisms of platelet adhesion and aggregation. , 1994, Seminars in hematology.
[34] A. S. Yuan,et al. Disposition of MK-852, a fibrinogen receptor antagonist, in rats and dogs. , 1994, Drug metabolism and disposition: the biological fate of chemicals.
[35] J. Hubbell,et al. Inhibition of thrombosis and intimal thickening by in situ photopolymerization of thin hydrogel barriers. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[36] R. Califf,et al. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa iritegrin for reduction of clinical restenosis: results at six months , 1994, The Lancet.
[37] Epic Investigators,et al. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. , 1994, The New England journal of medicine.
[38] S. Mousa,et al. Antithrombotic Effects of DMP 728, a Platelet GPIIb/IIIa Receptor Antagonist, in a Canine Model of Arterial Thrombosis , 1994, Journal of cardiovascular pharmacology.
[39] E. Topol,et al. Combination of platelet fibrinogen receptor antagonist and direct thrombin inhibitor at low doses markedly improves thrombolysis. , 1994, Circulation.
[40] Yukio Motoyama,et al. The pharmacology of the integrins , 1994, Medicinal research reviews.
[41] S. Schwartz,et al. Osteopontin promotes vascular cell adhesion and spreading and is chemotactic for smooth muscle cells in vitro. , 1994, Circulation research.
[42] S. Roux,et al. Experimental carotid thrombosis in the guinea pig. , 1994, Thrombosis and haemostasis.
[43] J. A. L. Pez,et al. The platelet glycoprotein Ib-IX complex. , 1994, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.
[44] C. Pally,et al. The Effects of Two Synthetic Glycoprotein II b/III a Antagonists, Ro 43-8857 and L-700,462, on Platelet Aggregation and Bleeding in Guinea-Pigs and Dogs: Evidence that Ro 43-8857 Is Orally Active , 1993, Thrombosis and Haemostasis.
[45] P. Nurden,et al. A review of the role of platelet membrane glycoproteins in the platelet-vessel wall interaction. , 1993, Bailliere's clinical haematology.
[46] H. Zerwes,et al. Platelet Aggregation and Fibrinogen Binding in Human, Rhesus Monkey, Guinea-Pig, Hamster and Rat Blood: Activation by ADP and a Thrombin Receptor Peptide and Inhibition by Glycoprotein IIb/IIIa Antagonists , 1993, Thrombosis and Haemostasis.
[47] E. Topol,et al. Clinical Trials of Platelet Receptor Inhibitors , 1993, Thrombosis and Haemostasis.
[48] F. Orr,et al. Localization of 13-hydroxyoctadecadienoic acid and the vitronectin receptor in human endothelial cells and endothelial cell/platelet interactions in vitro. , 1993, Blood.
[49] T. Olah,et al. Determination of MK-852, a new fibrinogen receptor antagonist, in plasma and urine by radioimmunoassay. , 1993, Journal of pharmaceutical and biomedical analysis.
[50] D. Faxon,et al. Pharmacologic prevention of restenosis after coronary angioplasty: review of the randomized clinical trials. , 1993, Coronary artery disease.
[51] P. Hadváry,et al. Low molecular weight, non-peptide fibrinogen receptor antagonists. , 1992, Journal of medicinal chemistry.
[52] H. Gralnick,et al. A monomeric von Willebrand factor fragment, Leu-504--Lys-728, inhibits von Willebrand factor interaction with glycoprotein Ib-IX [corrected]. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[53] T. Ryan,et al. The effect of antiplatelet therapy on platelet accumulation after experimental angioplasty in the rabbit iliac model. , 1992, International journal of cardiology.
[54] J. Moake,et al. Shear stress-induced von Willebrand factor binding to platelet glycoprotein Ib initiates calcium influx associated with aggregation. , 1992, Blood.
[55] R. Kramer,et al. β1 And β3 integrins have different roles in the adhesion and migration of vascular smooth muscle cells on extracellular matrix , 1992 .
[56] G. Feuerstein,et al. Antithrombotic Effects of a Platelet Fibrinogen Receptor Antagonist in a Canine Model of Carotid Artery Thrombosis , 1992, Stroke.
[57] F. Orr,et al. Up-regulated biosynthesis and expression of endothelial cell vitronectin receptor enhances cancer cell adhesion. , 1992, Cancer research.
[58] Richard O. Hynes,et al. Integrins: Versatility, modulation, and signaling in cell adhesion , 1992, Cell.
[59] M. Savage,et al. Multi-Hospital Eastern Atlantic Restenosis Trial. II: A placebo-controlled trial of thromboxane blockade in the prevention of restenosis following coronary angioplasty. , 1991, American heart journal.
[60] P. Serruys,et al. Prevention of Restenosis After Percutaneous Transluminal Coronary Angioplasty With Thromboxane A2‐Receptor Blockade: A Randomized, Double‐Blind, Placebo‐Controlled Trial , 1991, Circulation.
[61] M. Reidy,et al. Inhibition of neointimal smooth muscle accumulation after angioplasty by an antibody to PDGF , 1991, Science.
[62] V. Fuster,et al. Antithrombotic Therapy for Deep Arterial Injury by Angioplasty: Efficacy of Common Platelet Inhibition Compared With Thrombin Inhibition in Pigs , 1991, Circulation.
[63] F. Orr,et al. Endothelial cell damage by Walker carcinosarcoma cells is dependent on vitronectin receptor-mediated tumor cell adhesion. , 1991, The American journal of pathology.
[64] M. Reidy,et al. Proliferation of smooth muscle cells after vascular injury is inhibited by an antibody against basic fibroblast growth factor. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[65] K Watanabe,et al. The role of von Willebrand factor and fibrinogen in platelet aggregation under varying shear stress. , 1991, The Journal of clinical investigation.
[66] H. Weisman,et al. Monoclonal Antibodies to Platelet Glycoprotein IIb/IIIa as Antithrombotic Agents a , 1991, Annals of the New York Academy of Sciences.
[67] S. Albelda,et al. Integrins and other cell adhesion molecules , 1990, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[68] M. Reidy,et al. Role of platelets in smooth muscle cell proliferation and migration after vascular injury in rat carotid artery. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[69] M. Bednarek,et al. Platelet receptor recognition domain on the gamma chain of human fibrinogen and its synthetic peptide analogues. , 1989, Biochemistry.
[70] D. Cheresh,et al. Isolation and characterization of a platelet membrane protein related to the vitronectin receptor. , 1989, The Journal of biological chemistry.
[71] L Schwartz,et al. Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty. , 1988, The New England journal of medicine.
[72] V. Fuster,et al. Insights into the pathogenesis of acute ischemic syndromes. , 1988, Circulation.
[73] J. Moake,et al. Shear-induced platelet aggregation can be mediated by vWF released from platelets, as well as by exogenous large or unusually large vWF multimers, requires adenosine diphosphate, and is resistant to aspirin , 1988 .
[74] M. Ginsberg,et al. Cytoadhesins, Integrins, and Platelets , 1988, Thrombosis and Haemostasis.
[75] M. Poncz,et al. Comparison of cDNA-derived protein sequences of the human fibronectin and vitronectin receptor alpha-subunits and platelet glycoprotein IIb. , 1987, Biochemistry.
[76] Xiaoping Du,et al. Glycoprotein Ib and glycoprotein IX are fully complexed in the intact platelet membrane. , 1987, Blood.
[77] T. Ryan,et al. Platelet accumulation in experimental angioplasty: time course and relation to vascular injury. , 1987, Circulation.
[78] J. Moake,et al. Involvement of large plasma von Willebrand factor (vWF) multimers and unusually large vWF forms derived from endothelial cells in shear stress-induced platelet aggregation. , 1986, The Journal of clinical investigation.
[79] V. Fuster,et al. Deep arterial injury during experimental angioplasty: relation to a positive indium-111-labeled platelet scintigram, quantitative platelet deposition and mural thrombosis. , 1986, Journal of the American College of Cardiology.
[80] P. Hagen,et al. The role of aspirin and dipyridamole on vascular DNA synthesis and intimal hyperplasia following deendothelialization. , 1986, The Journal of surgical research.
[81] E Ruoslahti,et al. The effect of Arg-Gly-Asp-containing peptides on fibrinogen and von Willebrand factor binding to platelets. , 1985, Proceedings of the National Academy of Sciences of the United States of America.
[82] H. Zola,et al. Purification and preliminary characterization of the glycoprotein Ib complex in the human platelet membrane. , 1985, European journal of biochemistry.
[83] V. Fuster,et al. Balloon angioplasty. Natural history of the pathophysiological response to injury in a pig model. , 1985, Circulation research.
[84] B. Coller. A new murine monoclonal antibody reports an activation-dependent change in the conformation and/or microenvironment of the platelet glycoprotein IIb/IIIa complex. , 1985, The Journal of clinical investigation.
[85] T. Ryan,et al. Effect of antiplatelet therapy on restenosis after experimental angioplasty. , 1984, The American journal of cardiology.
[86] R. Erbel,et al. Percutaneous transluminal coronary angioplasty in patients with stable and unstable angina pectoris: analysis of early and late results. , 1983, American heart journal.
[87] A E Becker,et al. Transluminal coronary angioplasty and early restenosis. Fibrocellular occlusion after wall laceration. , 1983, British heart journal.
[88] J. Joist,et al. Role of cytoplasmic and releasable ADP in platelet aggregation induced by laminar shear stress. , 1983, The Journal of laboratory and clinical medicine.
[89] D. Waters,et al. Percutaneous Transluminal Coronary Angioplasty in Patients with Variant Angina , 1982, Circulation.
[90] W. Siegenthaler,et al. Nonoperative dilatation of coronary-artery stenosis: percutaneous transluminal coronary angioplasty. , 1979, The New England journal of medicine.
[91] A. Nurden,et al. Specific roles for platelet surface glycoproteins in platelet function , 1975, Nature.
[92] José A López,et al. The platelet glycoprotein Ib-IX complex , 2017 .
[93] T. Yasuda,et al. Antithrombotic Effects and Bleeding Time Prolongation with Synthetic Platelet GPIIb/llla Inhibitors in Animal Models of Platelet-Mediated Thrombosis , 1994, Thrombosis and Haemostasis.
[94] S. Mousa,et al. Antiplatelet and antithrombotic efficacy of DMP 728, a novel platelet GPIIb/IIIa receptor antagonist. , 1994, Circulation.
[95] A. Callow,et al. Inhibition of neointimal hyperplasia by blocking αvβ3 integrin with a small peptide antagonist GpenGRGDSPCA , 1994 .
[96] S. Mousa,et al. Antiplatelet efficacy and specificity of DMP728, a novel platelet GPIIb/IIIa receptor antagonist. , 1993, Cardiology.
[97] S. D’Souza,et al. Ligand Binding to GPIIb-IIIa: A Status Report , 1992, Seminars in thrombosis and hemostasis.
[98] B. Coller,et al. Platelet vitronectin receptor expression differentiates Iraqi-Jewish from Arab patients with Glanzmann thrombasthenia in Israel , 1991 .
[99] M. Reidy,et al. Role of basic fibroblast growth factor in vascular lesion formation. , 1991, Circulation research.
[100] G. Roth,et al. Developing relationships: arterial platelet adhesion, glycoprotein Ib, and leucine-rich glycoproteins. , 1991, Blood.
[101] R. Friedman,et al. SMOOTH MUSCLE CELL PROLIFERATION AND RE-ENDOTHELIALIZATION , 1977 .